Neonatal Screening Program For Heamoglobinopathies In Vidharbha Region (Central India)

Authors

  • Rakesh Kumar Jha, Ranjit Ambad , Gangaram Bhadarge , Deepti Shrivastava

Abstract

Hemoglobinopathies Are A Group Of Diseases That Are Characterized By Abnormal Hemoglobin Molecule Synthesis Or Synthesis Given By Families (Inherited). Sickle Cell Disease (Scd) Is A Blood Disorder Caused By A Defective Hemoglobin, Which Causes The Red Blood Cells To Be Damaged And Disabled. Anemia Is Caused By A Collapse Of Abnormal Red Blood Cells And Blockage Of Blood Vessels, Leading To Repeated Outbreaks Of Severe Pain And Organ Damage. Scd Affects Millions Of People Worldwide, But It Is Most Common In Ancestral People From Sub-Saharan Africa, The Western Hemisphere (South America, The Caribbean And Central America), Saudi Arabia, India And The Mediterranean Nations Such As Turkey, Greece, And Italy. Unless Other Children Are Successfully Treated With Blood Cells Or Bone Marrow, There Is No Commonly Available Cure For Scd.1

However, Due To The Difficulty Of Finding The Same Donor, Implantation Of Hematopoietic Stem Cell Implants Is Not Routinely Performed With Scd. As A Result, The Number Of People With Scd Receiving Transplants Is Very Low. In Addition, There Are A Number Of Risks Involved In Surgery, Including A 5% Mortality Rate. The Severity Of Clinical Complications In Scd, From Doses To Paralysis Symptoms To Severe Symptoms That Require Hospitalization. There Are Symptomatic Scd Treatments, And Neonatal (Nbs) Screening For Scd Can Help Reduce The Burden On Newborns And Adolescents With The Disease.

Published

2021-07-21

How to Cite

Rakesh Kumar Jha, Ranjit Ambad , Gangaram Bhadarge , Deepti Shrivastava. (2021). Neonatal Screening Program For Heamoglobinopathies In Vidharbha Region (Central India). Drugs and Cell Therapies in Hematology, 10(1), 830–838. Retrieved from https://www.dcth.org/index.php/journal/article/view/169

Issue

Section

Articles